SCHEMBL21773009

SCHEMBL21773009

CN(c1cnc(S(=O)(=O)Nc2cscn2)cc1C(F)(F)F)C1CCN(Cc2cc(F)ccc2F)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 20/20 1.00
SCN8A Q9UQD0 20/20 1.00
SCN5A Q14524 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21773044 0.87 SCN1A (1.00) SCN1ASCN8A
SCHEMBL21773047 0.87 SCN1A (1.00) SCN1ASCN8A
SCHEMBL21773259 0.86 SCN8A (1.00) SCN1ASCN8A
Trifluoroacetic Acid SCHEMBL28558196 0.85 SCN1A (0.89) SCN1ASCN8A
SCHEMBL21773147 0.84 SCN8A (1.00) SCN1ASCN8A
SCHEMBL21793952 0.84 SCN1A (0.72) SCN1ASCN8ASCN5A
Trifluoroacetic Acid SCHEMBL21773062 0.83 SCN8A (0.93) SCN1ASCN8A
Trifluoroacetic Acid SCHEMBL21773215 0.82 SCN1A (0.83) SCN1ASCN8A
SCHEMBL21773289 0.82 SCN8A (1.00) SCN1ASCN8A
SCHEMBL21773208 0.82 SCN8A (1.00) SCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112638898-A Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2021-04-09 CN claimed
CN-112638898-B Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2024-04-09 CN disclosed
CN-112638898-A Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2021-04-09 CN disclosed
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors XENON PHARMACEUTICALS INC. (CA) 2020-08-25 US disclosed
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors XENON PHARMACEUTICALS INC. (CA) 2020-08-25 US disclosed
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 US disclosed
WO-2020047312-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071313-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS SCN1A, SCN2A, SCN2B SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885
US-10752623-B2 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors SCN1A, SCN2A, SCN2B SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.